SCHEMBL876946

SCHEMBL876946

O=Cc1cc(F)c(Oc2ccc(C(F)(F)F)nc2)c(F)c1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALOX5AP P20292 1/20 0.41
FEN1 P39748 1/20 0.41
SCN9A Q15858 9/20 0.39
MRGPRX4 Q96LA9 1/20 0.38
ALDH1A1 P00352 2/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
POLB P06746 2/20 0.38
CASP6 P55212 1/20 0.37
TRPV4 Q9HBA0 1/20 0.37
GRM5 P41594 1/20 0.36
SCN10A Q9Y5Y9 5/20 0.36
SCN8A Q9UQD0 2/20 0.35
KDM4E B2RXH2 1/20 0.35
PLAAT3 P53816 1/20 0.35
PLAAT5 Q96KN8 1/20 0.35
PLAAT2 Q9NWW9 1/20 0.35
PLAAT4 Q9UL19 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL875647 0.84 ALDH1A1 (0.39) SCN9AMRGPRX4ALDH1A1L3MBTL1POLB
SCHEMBL15901354 0.82 ALDH1A1 (0.41) ALDH1A1L3MBTL1POLBCASP6KDM4E
SCHEMBL9103318 0.81 ALDH1A1 (0.37) ALDH1A1L3MBTL1POLBCASP6
SCHEMBL9107191 0.81 KDM4E (0.50) SCN9AMRGPRX4ALDH1A1L3MBTL1POLB
SCHEMBL30025467 0.81 ALOX5AP (0.42) ALOX5APFEN1ALDH1A1L3MBTL1POLB
SCHEMBL15901123 0.81 ALOX5AP (0.42) ALOX5APFEN1ALDH1A1L3MBTL1POLB
SCHEMBL23193915 0.80 SCN9A (0.33) SCN9AALDH1A1L3MBTL1POLBCASP6
SCHEMBL31276498 0.80 SCN9A (0.33) SCN9AALDH1A1L3MBTL1POLBCASP6
SCHEMBL15096505 0.80 ALDH1A1 (0.39) ALDH1A1L3MBTL1POLBCASP6GRM5
SCHEMBL30026175 0.80 ALDH1A1 (0.39) ALDH1A1L3MBTL1POLBCASP6GRM5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4174070-B1 TRICYCLIC PYRIMIDINONE COMPOUND, PREPARATION METHOD THEREFOR, AND COMPOSITION AND USE THEREOF NEUSCO BIOTECH LTD (CN) 2025-10-29 EP disclosed
CN-119161343-A Bridged pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof 上海深势唯思科技有限责任公司 2024-12-20 CN disclosed
CN-119143780-A Lp-PLA2 inhibitor, preparation method thereof, pharmaceutical composition and application thereof 上海深势唯思科技有限责任公司 2024-12-17 CN disclosed
CN-119080800-A Tricyclic pyrimidinone compounds, preparation method thereof, pharmaceutical composition and application thereof 上海深势唯思科技有限责任公司 2024-12-06 CN disclosed
US-20240300965-A1 COMPOUNDS GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-09-12 US disclosed
US-11999746-B2 Compounds GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) 2024-06-04 US disclosed
CN-113912622-B Tricyclic pyrimidinone compounds, methods of making, compositions and uses thereof 上海纽思克生物科技有限公司 2023-12-01 CN disclosed
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION NEUSCO BIOTECH LIMITED (CN) 2023-11-09 US disclosed
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION NEUSCO BIOTECH LIMITED (CN) 2023-11-09 US disclosed
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION NEUSCO BIOTECH LIMITED (CN) 2023-11-09 US disclosed
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2013-07-11 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
US-20130030012-A1 COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 US disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2013013503-A1 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2013014185-A1 BICYCLIC PYRIMIDONE COMPOUNDS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2013013503-A1 2,3-DIHYDROIMIDAZO[1,2-C] PYRIMIDIN-5(1H)-ONE COMPOUNDS USE AS LP-PLA2 INHIBITORS GLAXO GROUP LIMITED (GB) 2013-01-31 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed
WO-2012037782-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES GLAXO GROUP LIMITED (GB) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300965-A1 COMPOUNDS PLAAT2, PLA2G12A, PLA2G1B ALOX5AP 40/4885FEN1 3847/4885SCN9A 2966/4885
US-20130030012-A1 COMPOUNDS LPCAT1, PLA2G7, PLAAT2 ALOX5AP 37/4885FEN1 2954/4885SCN9A 4057/4885
US-11999746-B2 Compounds PLAAT2, PLA2G12A, PLA2G1B ALOX5AP 40/4885FEN1 3847/4885SCN9A 2966/4885
US-20130178488-A1 TRICYCLIC COMPOUNDS, PREPARATION METHODS, AND THEIR USES LIPG, PCSK9, ENPP2 ALOX5AP 28/4885FEN1 845/4885SCN9A 4613/4885
US-20230357268-A1 PREPARATION AND APPLICATION OF TRICYCLIC PYRIMIDINONE COMPOUND AND ITS COMPOSITION PLA2G1B, PLA2G4B, PLA2G5 ALOX5AP 57/4885FEN1 1009/4885SCN9A 2998/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.